Numbers 3 Flashcards
1
Q
Sensitivity and specificity of IOTA
A
95%
91%
2
Q
RMI score >200 sensitivity and specificity
A
78%
87%
3
Q
Risk chemical peritonitis in dermoid cyst spillage
A
0.2%
4
Q
% reduction in hirsutism by weight reduction 5-10%
A
40-55%
5
Q
% reduction in hair growth with Eflornithine
A
60%
6
Q
% of POI who conceive
A
10-15%
7
Q
Number of follicles by puberty
A
0.5 million
8
Q
% POI in Fragile X Syndrome
A
13-26%
9
Q
% POI with osteopenia
A
50%
10
Q
Precocious puberty incidence
A
1:5000-10,000
11
Q
% of idiopathic cause of central precocious puberty
A
74%
12
Q
% of metabolic syndrome in women with PCOS
A
33%
13
Q
Risk of CHD and stroke in PCOS
Risk in metabolic syndrome
A
2x
3-6x
14
Q
Risk T2DM in PCOS + metabolic syndrome
A
5x
15
Q
Risk OSA in PCOS
A
30x
16
Q
Incidence of congenital uterine abnormalities
A
3%
90% septate uterus
5% bicornuate
5% didelphic
17
Q
% of MRKH syndrome with renal tract abnormality
A
40%
18
Q
% delayed puberty
A
3%
19
Q
Incidence of puerperial genital haematomas
A
1:700
20
Q
% women who choose ELCS after previous 3rd/4th degree tear
A
25%
21
Q
Rate of postpartum psychosis
A
1:1000
22
Q
VIN 3 progression rate
A
6.5%
23
Q
% VIN will show invasive cancer on excision
A
12-17%
24
Q
Risk of VIN without WLE progression to cancer in 8 years
A
40-60%
25
Risk VIN with WLE progression to cancer
4%
26
Risk of leiomyosarcoma in women undergoing surgery for presumed fibroids <40yo
<1:500
27
Risk of leiomyosarcoma in women undergoing surgery for presumed fibroids 75-79yo
1:100
28
% vulval carcinoma that is SCC
90%
29
Risk of vulval ca recurrence if disease free margin >8mm
0%
30
Risk of vulval ca recurrence if disease free margin <8mm
47%
31
Risk of fetal loss if dysgerminoma removal in pregnancy
25%
32
% that adnexal mass is not ovarian
10%
33
% of operable vulval cancer that will have lymph node spread
30%
34
Prevalence of ovarian cysts in postmenopausal women
5-17%
35
CA125 >30 sensitivity and specificity for ovarian ca
81%
| 75%
36
IOTA sensitivity and specificity for ovarian cancer
95%
| 91%
37
RMI sensitivity and specificity for ovarian cancer
78%
| 87%
38
UK ovarian cancer complete cytoreduction %
<12%
39
Every 10% improvement in maximum cytoreduction improves survival by what %
5%
40
OC response rate in platinum resistant recurrence
10-20%
41
OC response rate in platinum refractory recurrence
<10%
42
OC response rate in platinum partially (>6/12, <12/12) sensitive recurrence
25-30%
43
OC response rate in platinum sensitive (>12/12) recurrence
40-75%
44
5yr survival Stage 1 BOT
95-97%
45
5yr survival Stage 3 BOT
50-86%
46
10yr survival BOT
70-80%
47
Relapse of BOT with radical treatment
2.5-5.7%
48
Relapse of BOT with unilateral SPO
0-20%
49
Relapse of BOT with cystectomy
12-58%
50
Incidence of invasive disease in recurrent BOTs
8-73%
51
Survival % for early stage germ cell tumour
90%
52
Survival % for advanced germ cell tumour
75-80%
53
% of MOGCT recurrence that occurs within 1st year
75%
54
5yr survival rate for Stage 4 epithelial ovarian cancer
5%
55
5yr survival rate for Stage 3 epithelial ovarian cancer
20%
56
5yr survival rate for Stage 2 epithelial ovarian cancer
40%
57
5yr survival rate for Stage 1 epithelial ovarian cancer
90%
58
Overall 5 yr survival for epithelial ovarian cancer
45%
59
Sporadic FH of EOC - 1 family member - risk of EOC
4-5%
60
Sporadic FH of EOC - 2 family members - risk of EOC
7%
61
Hereditary EOC - 2 first degree relatives - risk of EOC
13-50%
62
BRCA1 risk of ovarian cancer
35-46%
63
BRCA2 risk of ovarian cancer
13-23%
64
Lynch syndrome risk of ovarian cancer
3-14%
65
Peutz Jeghers risk of ovarian cancer
20%
66
% that risk reducing surgery (rrBSO) reduces breast cancer in BRCA carriers
30-75%
67
% risk of peritoneal cancer in BRCA carriers
2%
68
% occult malignancy in risk reducing surgery (rrBSO)
4-8%
69
Risk of endometrial cancer with Lynch syndrome
40-60%
70
% of STICs seen in prophylactic BSO for primary peritoneal disease
10-15%
71
% STICs in serous ovarian carcinoma
48-61% (small studies)
72
% that risk reducing surgery (rrBSO) can reduce ovarian/fallopian tube/peritoneal cancer in BRCA carriers
80%
73
% risk reduction for EOC with tubal ligation/removal
29%
74
% risk reduction of serous OC or primary peritoneal cancer with salpingectomy
60%
75
% that ovarian cancer is hereditary
10-15%
76
% 1st trimester miscarriage in radical trachelectomy
% 2nd trimester miscarriage
% of full term pregnancies
16-20% (similar to BG)
8-10%
70-75%
77
Radical trachelectomy recurrence
4.2-5.6%
78
% of conversion to laparotomy for lap treatment of endometrial cancer
26%
79
% LN involvement in cervical ca Stage 1A1
1%
80
% LN involvement in cervical ca Stage 1A2
5%
81
% cervical cancer caused by HPV 16 & 18
70-80%
82
% vulval and oropharyngeal cancer caused by HPV 16 & 18
40-50%
83
% anal cancers caused by HPV 16 & 18
70-80%
84
High risk HPV screen sensitivity and specificity
96%
| 99%
85
% VIN caused by HPV 16
67.5%
86
% VC caused by HPV 16
32.2%
87
5yr survival rate stage 1 endometrial cancer
85-90%
88
5yr survival rate stage 2 endometrial cancer
65%
89
5yr survival rate stage 3 endometrial cancer
45-60%
90
5yr survival rate stage 4 endometrial cancer
15%
91
% cervical cancer that are squamous
70%
92
Overall cervical cancer 5yr survival rate
68%
93
Risk a TOA in postmenopausal woman
47%
94
% CPP after 1 episode of TOA
12%
95
% CPP after 2 episodes of TOA
30%
96
% CPP after 3 episodes of TOA
67%
97
% PID is polymicrobial
30-40%
98
% PID due to chlamydia/gonorrhoea
25%
99
Cure rate of pelvic exenteration in recurrent cervical cancer
30-50%
100
% CIN that will regress
50%
101
Recurrence rate of ectopic
18%
102
Severe polyhydramnios
>35cm
103
Moderate polyhydramnios
30-34.9cm
104
Mild polyhydramnios
25-29.9cm
105
Incidence of endometrial cancer
28:100,000
106
% of thecomas that are androgenic
10%
107
% of abnormalities on USS that are cystic hygroma
35%
108
% cystic hygromas associated with fetal chromosomal abnormalities
50%
